Merck in talks to buy cancer biotech Seagen: report - Fox Business

Merck & Co is reportedly in talks to acquire biotech company Seagen Inc. in a nearly $40 billon deal that would add to the company's cancer drug portfolio.

Drugmaker Merck & Co is reportedly in advanced talks to buy cancer-focused biotech company Seagen Inc. The deal could be worth roughly $40 billion or more, according to the Wall Street Journal. … [+1597 chars]

full article...